Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:EIGR NASDAQ:ITMR NASDAQ:KLDO NYSE:NFH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.41+1.7%$6.36$3.93▼$7.54$272.80M1.421.05 million shs1.04 million shsEIGREiger BioPharmaceuticals$4.35$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/AKLDOKaleido Biosciences$0.01$0.00▼$0.35$6.39M-0.0610,546 shsN/ANFHNew Frontier Health$11.95$11.66$8.30▼$11.96$1.58B0.13508,600 shs2.18 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+1.69%-0.55%-22.16%-8.37%-13.16%EIGREiger BioPharmaceuticals0.00%0.00%0.00%0.00%0.00%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%KLDOKaleido Biosciences0.00%0.00%+1,900.00%+1,900.00%+1,900.00%NFHNew Frontier Health0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.41+1.7%$6.36$3.93▼$7.54$272.80M1.421.05 million shs1.04 million shsEIGREiger BioPharmaceuticals$4.35$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/AKLDOKaleido Biosciences$0.01$0.00▼$0.35$6.39M-0.0610,546 shsN/ANFHNew Frontier Health$11.95$11.66$8.30▼$11.96$1.58B0.13508,600 shs2.18 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+1.69%-0.55%-22.16%-8.37%-13.16%EIGREiger BioPharmaceuticals0.00%0.00%0.00%0.00%0.00%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%KLDOKaleido Biosciences0.00%0.00%+1,900.00%+1,900.00%+1,900.00%NFHNew Frontier Health0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.83Moderate Buy$19.50260.44% UpsideEIGREiger BioPharmaceuticals 0.00N/AN/AN/AITMRItamar Medical 0.00N/AN/AN/AKLDOKaleido Biosciences 0.00N/AN/AN/ANFHNew Frontier Health 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KLDO, EIGR, NFH, ABEO, and ITMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ABEOAbeona TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)8/18/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/15/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $20.007/14/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 10/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$400K693.55N/AN/A$1.01 per share5.36EIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00ITMRItamar Medical$41.03M12.12N/AN/AN/A∞KLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNNFHNew Frontier Health$346.44M4.55N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.707.73N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)EIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/AITMRItamar MedicalN/A-$1.35N/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ANFHNew Frontier Health-$73.26M-$0.43N/A∞N/AN/AN/AN/AN/ALatest KLDO, EIGR, NFH, ABEO, and ITMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AITMRItamar MedicalN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/ANFHNew Frontier HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65EIGREiger BioPharmaceuticalsN/A3.313.24ITMRItamar MedicalN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/ANFHNew Frontier HealthN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%EIGREiger BioPharmaceuticals62.46%ITMRItamar Medical42.19%KLDOKaleido Biosciences81.56%NFHNew Frontier HealthN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%EIGREiger BioPharmaceuticals4.22%ITMRItamar MedicalN/AKLDOKaleido Biosciences9.00%NFHNew Frontier HealthN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million47.74 millionOptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableITMRItamar Medical25716.11 millionN/ANot OptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionableNFHNew Frontier Health3,309131.85 millionN/ANot OptionableKLDO, EIGR, NFH, ABEO, and ITMR HeadlinesRecent News About These CompaniesRhythm, Sound And Music: The New Frontier In Health InnovationFebruary 9, 2025 | forbes.comFrontier Health launches video challenge to combat bullying and spread positivityFebruary 5, 2025 | msn.comThe Digital Health Frontier: Redefining Healthcare With Tech In 2025January 31, 2025 | forbes.comVirtual medicine’s next frontier | Philly Health InsiderNovember 6, 2024 | msn.comHighland High School vs. Frontier High School Football Live Stream, TV Info - Thursday, October 24October 23, 2024 | sfgate.com‘The next frontier’: Hawaii’s health care, industrial fields get high-tech upgradeOctober 19, 2024 | msn.comExploring New Frontiers of Faculty ExcellenceOctober 15, 2024 | sciencex.comSFrontier Food Hub/National Center - Unitarian Universalist FellowshipOctober 13, 2024 | grantcountybeat.comGFrontier House re-opening stalled due to restoration road bumpsOctober 12, 2024 | msn.comFrontier Airlines to offer nonstop flights from CVG to this sunny cityOctober 5, 2024 | news.yahoo.comThe Next Frontier in Nursing: Embracing Tech & AIOctober 2, 2024 | marketscale.comMTHE FRONTIER: A probe into Cleveland County jail deaths will include a look at medical provider Turn Key HealthOctober 1, 2024 | tahlequahdailypress.comTNew Horizons Behavioral Health unveils new mobile unitSeptember 18, 2024 | msn.comDetroit's Health Care Frontier: Henry Ford Health Begins Monumental $2.2 Billion Expansion ProjectSeptember 14, 2024 | hoodline.comHThe Dirt: New health clinic planned for SpokaneSeptember 13, 2024 | spokesman.comSHighland High School vs. Frontier High School Football Live Stream, TV Info - Saturday, September 14September 12, 2024 | sfgate.comWeight loss frontier: New medicine shows early promiseSeptember 12, 2024 | yahoo.comNo-frills US carrier Frontier hikes margin forecast on moderating capacity growthSeptember 12, 2024 | reuters.comWhat The Next Frontier Of Soil Health Might Look LikeSeptember 11, 2024 | growingproduce.comGFrontier Home Medical moves to a new location and celebrates grand openingSeptember 7, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLDO, EIGR, NFH, ABEO, and ITMR Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.41 +0.09 (+1.69%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.38 -0.04 (-0.65%) As of 10/3/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Eiger BioPharmaceuticals NASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.Itamar Medical NASDAQ:ITMRItamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.Kaleido Biosciences NASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.New Frontier Health NYSE:NFHNew Frontier Health Corporation provides healthcare services in the People's Republic of China. It operates a network of hospital inpatient departments and integrated outpatient clinics, including satellite feeder clinics. The company's facilities include 24/7 emergency rooms, intensive care units, neonatal intensive care units, operating rooms, clinical laboratories, radiology, and blood banking services. It operates five hospitals and nine clinics in northern China; two hospitals and four clinics in eastern China; and two hospitals and one clinic in southern China. The company is based in Beijing, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? A Copper Catalyst: Why Freeport-McMoRan Is Positioned to Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
